Efficacy and safety of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph+ CML or relapsed/refractory Ph+ ALL: a 36-month analysis of a phase I and II study-Reference-Cited by-同舟云学术

Efficacy and safety of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph+ CML or relapsed/refractory Ph+ ALL: a 36-month analysis of a phase I and II study

Published:2012-02-23 Issue:4 Volume:95 Page:409-419
ISSN:0925-5710
Container-title:International Journal of Hematology
language:en
Short-container-title:Int J Hematol

Author:

Usuki Kensuke,Tojo Arinobu,Maeda Yasuhiro,Kobayashi Yukio,Matsuda Akira,Ohyashiki Kazuma,Nakaseko Chiaki,Kawaguchi Tatsuya,Tanaka Hideo,Miyamura Koichi,Miyazaki Yasushi,Okamoto Shinichiro,Oritani Kenji,Okada Masaya,Usui Noriko,Nagai Tadashi,Amagasaki Taro,Wanajo Aira,Naoe Tomoki

Publisher

Springer Science and Business Media LLC

Subject

Hematology

Link

http://link.springer.com/content/pdf/10.1007/s12185-012-1026-9.pdf

Reference31 articles.

1. Druker BJ, Guilhot F, O’Brien SG, Gathmann I, Kantarjian H, Gattermann N, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355:2408–17.

2. Hochhaus A, O’Brien SG, Guilhot F, Druker BJ, Branford S, Foroni L, et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia. 2009;23:1054–61.

3. Hughes TP, Hochhaus A, Branford S, Muller MC, Kaeda JS, Foroni L, et al. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS). Blood. 2010;116:3758–65.

4. de Lavallade H, Apperly JF, Khorashad JS, Milojkovic D, Reid AG, Bua M, et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol. 2008;26:3358–63.

5. Tauchi T, Kizaki M, Okamoto S, Tanaka H, Tanimoto M, Inokuchi K, et al. Seven-year follow-up of patients receiving imatinib for the treatment of newly diagnosed chronic myelogenous leukemia by the TARGET system. Leuk Res. 2011;35:585–90.

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The potential role of RNA sequencing in diagnosing unexplained insensitivity to conventional chemotherapy in pediatric patients with B-cell acute lymphoblastic leukemia;BMC Medical Genomics;2024-05-29

2. Hematological Adverse Events with Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia: A Systematic Review with Meta-Analysis;Cancers;2023-08-31

3. Hepatotoxicity of Small Molecule Protein Kinase Inhibitors for Cancer;Cancers;2023-03-14

4. Is dose modification or discontinuation of nilotinib necessary in nilotinib-induced hyperbilirubinemia?;World Journal of Meta-Analysis;2021-12-28

5. Nilotinib-induced liver injury;Medicine;2020-09-04